Automated Compounding Device (Oncology) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (Gravimetric Compounding System, Volumetric Compounding System), By End User (Hospitals, Chemotherapy Centers, Others), By Region, By Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 338.26 Million
CAGR (2026-2031)	8.17%
Fastest Growing Segment	Volumetric Compounding System
Largest Market	North America
Market Size (2031)	USD 541.87 Million

Market Overview

The Global Automated Compounding Device (Oncology) Market will grow from USD 338.26 Million in 2025 to USD 541.87 Million by 2031 at a 8.17% CAGR. Automated compounding devices for oncology are specialized robotic systems designed to prepare hazardous chemotherapy medications with high precision while minimizing human exposure to toxic substances. The market growth is primarily driven by the critical need to enhance medication safety by reducing compounding errors and the increasing global prevalence of cancer which demands higher volumes of chemotherapy preparations. According to the American Society of Health-System Pharmacists, in 2024, technologies to assist sterile product preparation were utilized in 62.8% of hospitals. This data underscores the rising reliance on automation to ensure accuracy and compliance in hazardous drug handling.

Despite the clear safety benefits, the expansion of this market faces a significant hurdle due to the substantial capital investment required for these complex systems. The high initial costs of acquisition and implementation, coupled with the expenses associated with ongoing maintenance and staff training, often deter smaller healthcare facilities from adopting this technology. Consequently, budget constraints remain a primary barrier preventing widespread implementation across all tiers of healthcare providers.

Key Market Drivers

The rising global prevalence of cancer and the subsequent surge in chemotherapy demand serve as the primary catalysts for the adoption of automated compounding devices in oncology. As patient volumes increase, hospital pharmacies face mounting pressure to produce sterile chemotherapy preparations at a scale that manual processes cannot sustainably support. Automation addresses this volume challenge by significantly increasing throughput while maintaining the rigorous sterility required for immunocompromised patients. This necessity is highlighted by the escalating disease burden; According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, it was projected that over 2,041,000 new cancer cases would be diagnosed in the United States alone that year. This data indicates a critical trajectory where manual compounding methods will become insufficient to meet the growing clinical needs.

Simultaneously, a heightened focus on occupational safety and exposure mitigation is compelling healthcare facilities to transition toward robotic systems. Handling hazardous antineoplastic drugs poses severe health risks to pharmacy staff, including potential mutagenic and carcinogenic effects from long-term exposure. Regulatory bodies are responding with stricter guidelines that necessitate containment strategies often best achieved through automation. According to the National Institute for Occupational Safety and Health, December 2024, in the 'List of Hazardous Drugs in Healthcare Settings, 2024', 25 new drugs were added to the hazardous category, reinforcing the expanding scope of substances requiring strict containment. The shift toward technology is further evidenced by broader industry trends; According to Pharmacy Times, September 2025, in the 'Intelligent Pharmacy' article, nearly 50% of global healthcare organizations planned to integrate AI-driven automation into their workflows by the end of the year.

Download Free Sample Report

Key Market Challenges

The substantial capital investment required for automated compounding devices acts as a significant restraint on market expansion, particularly for smaller healthcare facilities. Procurement involves not only the high purchase price of the robotic systems but also extensive costs related to facility modifications, software integration, and specialized personnel training. These financial demands create a barrier for community hospitals and rural centers that operate on restricted budgets, preventing them from transitioning away from manual chemotherapy preparation. As a result, the market remains heavily skewed toward large academic research centers, limiting broader commercial penetration.

This economic hurdle is evident in adoption metrics across major healthcare regions. According to the European Association of Hospital Pharmacists, in 2024, fewer than 30% of hospital pharmacies in Europe had fully or partially adopted automation technologies. This statistic illustrates that despite the critical need for safety in oncology compounding, the financial burden of these technologies stifles widespread implementation. Consequently, the market struggles to capture volume in lower-tier segments, directly hampering overall industry growth.

Key Market Trends

The shift toward gravimetric verification technologies represents a fundamental evolution in safety, moving beyond visual volumetric methods. This trend is gaining traction as facilities recognize that weight-based verification provides a precise method to ensure the concentration of oncology ingredients. Scale-based checks detect deviations that manual methods miss, significantly mitigating dosing errors. However, adoption remains early due to operational complexity; According to Pharmacy Practice News, December 2024, in the 'Is IVWMS Adoption Rate Fast Enough?' article, gravimetrics to verify dose, amount, and volume was utilized by only 7.7% of hospital pharmacies overall in 2023.

The rise of personalized medicine and genomic-based dosing is reshaping the market by demanding higher precision for patient-specific chemotherapy. Treatments now rely on biomarker-driven therapies requiring exact dosages tailored to an individual’s genetic profile, necessitating the accuracy that only robotic systems can consistently deliver. This forces compounding devices to adapt to complex batch sizes and handle high-value biologics with zero waste. This trajectory is highlighted by regulatory trends; According to the Personalized Medicine Coalition, May 2025, in the 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024' report, the FDA approved 18 new personalized medicines in 2024, representing 38% of newly approved therapeutic molecular entities.

Segmental Insights

The Volumetric Compounding System represents the fastest-growing segment in the Global Automated Compounding Device (Oncology) Market. This rapid expansion is driven by the technology's ability to offer a cost-effective and efficient alternative to manual preparation methods, which are prone to human error. Volumetric systems significantly enhance operational throughput in hospital pharmacies by automating the precise measurement of hazardous chemotherapy agents, thereby ensuring medication consistency and patient safety. Furthermore, the versatility of these devices in managing varying fluid volumes aligns effectively with the increasing demand for personalized oncology therapies, fostering their widespread adoption in healthcare facilities.

Regional Insights

North America maintains a leading position in the global automated compounding device market for oncology, driven largely by strict adherence to safety standards for hazardous drug handling. The implementation of guidelines such as United States Pharmacopeia General Chapter 800 compels healthcare facilities to adopt automation to limit staff exposure to toxic chemotherapy agents. Additionally, high healthcare expenditure and a strategic focus on minimizing medication errors support the integration of these systems. The presence of established clinical infrastructure further allows for the efficient deployment of compounding technologies across the region.

Recent Developments

• In October 2025, Omnicell, Inc. announced that Ballad Health had expanded its adoption of automated pharmacy technology by installing three IVX Station compounding robots at its Central Fill Pharmacy in Bristol Regional Medical Center. These robotic systems, designed to automate the preparation of intravenous medications, were implemented to eliminate manual compounding tasks, ensure reliability in IV preparation, and reduce the risk of errors and contamination. This installation built upon the health system's previous deployment of central pharmacy dispensing robots, creating a centralized hub that combines both dispensing and sterile compounding robotics to support medication distribution across its network of hospitals.
• In October 2024, Fresenius Kabi and Cellular Origins, a TTP Company, entered into a development agreement to integrate their respective technologies for the scalable automation of cell and gene therapy manufacturing. The collaboration aimed to physically and digitally combine Fresenius Kabi’s cell therapy processing systems, specifically the Cue Cell Processing System, with Cellular Origins’ Constellation robotic platform. This partnership was established to enable fully automated, scalable production of personalized therapies, including oncology treatments, by streamlining workflows and reducing the reliance on manual labor in manufacturing environments.
• In August 2024, Grifols installed its Kiro Oncology robot at the Trinity St James’s Cancer Institute in Dublin, marking the first implementation of this automated system in a hospital in Ireland or England. The robotic system was adopted to automate the compounding of cytotoxic chemotherapy drugs, thereby enhancing patient safety through precise dosing and protecting pharmacy staff from exposure to hazardous medications. The technology features two robotic arms and advanced sensors to perform gravimetric and volumetric checks, ensuring the accuracy and traceability of each prepared dose while optimizing the workflow within the hospital's pharmacy.
• In April 2024, Comecer unveiled a new robotic aseptic filling line designed for the handling of dual-chamber syringes and pharmaceutical vials, which are critical formats for various injectable therapies including those in oncology. The system was developed to offer a comprehensive, integrated solution that ensures high standards of safety, efficiency, and regulatory compliance in pharmaceutical manufacturing. This launch, which highlighted the company's focus on automation in aseptic processing, utilized advanced robotics to minimize human intervention and contamination risks during the filling and finishing of sterile products.

Key Market Players

• Baxter International Inc.
• B. Braun SE.
• COMECER S.p.A.
• ARxIUM Inc.
• Omnicell Inc.
• Grifols, S.A.
• Weibond Technology
• Equashield LLC.
• ICU Medical, Inc
• NewIcon Oy

By Technology	By End User	By Region
Gravimetric Compounding System Volumetric Compounding System	Hospitals Chemotherapy Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Automated Compounding Device (Oncology) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Automated Compounding Device (Oncology) Market, By Technology:

• Gravimetric Compounding System
• Volumetric Compounding System

• Automated Compounding Device (Oncology) Market, By End User:

• Hospitals
• Chemotherapy Centers
• Others

• Automated Compounding Device (Oncology) Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE